English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/135032
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Therapeutic Efficacy of Stable Analogues of Vasoactive Intestinal Peptide against Pathogens

AuthorsCampos-Salinas, Jenny; Cavazzuti, A.; O'Valle, Francisco; Forte-Lago, Irene; Caro, Marta; Beverley, S. M.; Delgado, M.; González-Rey, Elena
KeywordsAntimicrobial Peptides
Lipopolysaccharide (LPS)
Vasoactive Intestinal Peptide
Cutaneous Leishmaniasis
Issue Date4-Apr-2014
PublisherAmerican Society for Biochemistry and Molecular Biology
CitationJournal of Biological Chemistry
AbstractVasoactive intestinal peptide (VIP) is an anti-inflammatory neuropeptide recently identified as a potential antimicrobial peptide. To overcome the metabolic limitations of VIP, we modified the native peptide sequence and generated two stable synthetic analogues (VIP51 and VIP51(6–30)) with better antimicrobial profiles. Herein we investigate the effects of both VIP analogues on cell viability, membrane integrity, and ultrastructure of various bacterial strains and Leishmania species. We found that the two VIP derivatives kill various non-pathogenic and pathogenic Gram-positive and Gram-negative bacteria as well as the parasite Leishmania major through a mechanism that depends on the interaction with certain components of the microbial surface, the formation of pores, and the disruption of the surface membrane. The cytotoxicity of the VIP derivatives is specific for pathogens, because they do not affect the viability of mammalian cells. Docking simulations indicate that the chemical changes made in the analogues are critical to increase their antimicrobial activities. Consequently, we found that the native VIP is less potent as an antibacterial and fails as a leishmanicidal. Noteworthy from a therapeutic point of view is that treatment with both derivatives increases the survival and reduces bacterial load and inflammation in mice with polymicrobial sepsis. Moreover, treatment with VIP51(6–30) is very effective at reducing lesion size and parasite burden in a model of cutaneous leishmaniasis. These results indicate that the VIP analogues emerge as attractive alternatives for treating drug-resistant infectious diseases and provide key insights into a rational design of novel agents against these pathogens.
Publisher version (URL)http://www.jbc.org/content/early/2014/04/04/jbc.M114.560573
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
J. Biol. Chem.-2014-Campos-Salinas-14583-99 (2).pdf4,01 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.